Tuesday, April 5, 2022

Eli Lilly wins FDA’s emergency nod for COVID antibody—but thanks to mixed data, it’s limited


The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power.

The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it’s an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCellera.

The OK comes with some caveats. It’s limited to patients 12 years and older who aren’t hospitalized, but who are at high risk of developing severe illness, including elderly people and those with certain underlying conditions. And Lilly is advising infusion within 10 days of symptom onset.

Lilly said it will immediately start shipping the drug to distributor AmerisourceBergen, and it expects to manufacture up to 1 million doses of the single-dose therapy by the end of 2020. The U.S. government secured 300,000 doses in a recent $375 million deal and will handle allocating it to providers around the country.

The lack of a specific definition for “high risk” has one industry watcher complaining.

“We expect this limited indication to be highly confusing to the community physicians and urgent care centers that see many COVID cases, and even in nursing homes and hospital ERs this labeling and the determination of risk will be confusing,” SVB Leerink analyst Geoffrey Porges wrote in an investor note on Tuesday.

In clinical trials, Lilly found that patients with an inadequate early immune response to the virus were likely to have higher viral loads and a higher risk of hospitalization—and were thus the most likely to benefit from antibody treatment, Porges noted. But there is no word on how testing for viral load or immune response could be applied in the real world, he added.

Bamlanivimab was discovered by AbCellera and scientists at the National Institute of Allergy and Infectious Diseases (NIAID) in a blood sample from one of the first U.S. patients who recovered from COVID-19.

The drug is not omnipotent when it comes to treating COVID-19. The NIAID recently scrapped the bamlanivimab portion of a phase 3 trial in hospitalized patients after an independent data monitoring panel found it was unlikely to improve outcomes over placebo.

RELATED: Lilly links COVID-19 antibody to reduced hospitalization rate

Even the trial data underpinning the EUA—interim results from the ongoing phase 2 Blaze-1 trial—showed mixed results. For instance, the drug didn’t top placebo at clearing the virus by day 11, which was the study’s primary endpoint.

Plus, the fact that the highest dose tested performed even worse than the middle dose is simply confusing.

The current approval is for the lowest dose tested, 700 mg. The drug did cut the risk of hospitalizations and emergency room visits within 28 days after treatment to about 3%, from placebo’s 10%, among high-risk patients. The FDA pointed to that benefit as “the most important evidence that bamlanivimab may be effective.”  

Using an antibody to turbocharge the immune system to fight the novel coronavirus is an idea widely explored by many biopharma companies. Perhaps the most well-known among them is Regeneron, whose antibody cocktail, called REGN-COV2, was used as part of President Donald Trump’s treatment after he caught the virus.

Regeneron has also asked the FDA to authorize REGN-COV2 for emergency use in outpatients. Results from a phase 2/3 clinical trial linked the antibody cocktail to a 57% decrease in medical visits within 29 days after treatment, with the effect more pronounced in high-risk patients.

The Regeneron therapy also beat placebo at reducing viral load through day 7. However, the drug recently hit a snag with a trial in hospitalized patients: An independent data monitoring committee recommended halting enrollment of severely ill patients because of safety concerns.

Lilly has its own antibody combo, too—bamlanivimab paired with etesevimab (LY-CoV016/JS016), which it licensed from China’s Junshi Biosciences. In Blaze-1, the duo reduced viral load, clinical symptoms, COVID-related hospitalizations and ER visits. Lilly plans to request an emergency authorization for the combo as early as this month, Lilly’s Chief Scientific Officer Daniel Skovronsky told investors on a conference call in late October.

RELATED: Eli Lilly may face FDA warning letter after recent inspection at COVID-19 antibody plant found more issues: report

Now that bamlanivimab has won an EUA, Lilly needs to move carefully with manufacturing to ensure supply. An FDA inspection a year ago at the company’s Branchburg, New Jersey, facility, found inadequate “control of computer systems,” including deleted manufacturing data, Reuters reported. The site is one of five plants that make the antibody drug. Although the problem wasn’t tied to the COVID treatment, a potential FDA warning letter could hurt output.

Under the FDA authorization, Lilly will set up an independent third party to review batch records and other data related to bamlanivimab quality at the Branchburg site. Apart from its internal capacity, Lilly’s has tapped the likes of Amgen and Fujifilm Diosynth Biotechnologies to help scale up manufacturing.

Besides the anti-SARS-CoV-2 antibodies, Lilly’s rheumatoid arthritis med Olumiant is also under FDA review for emergency use in hospitalized COVID-19 patients. Adding the JAK inhibitor to Gilead Sciences’ Veklury, also known as remdesivir, further reduced time to recovery by 12.5% and improved the odds of clinical improvement, according to data from the NIAID-run ACTT-2 trial.

RELATED: COVID-19 fighter remdesivir racks up $873M as Gilead plays defense on unflattering WHO data

Bamlanivimab marks the fourth COVID drug the FDA has authorized for emergency use during the pandemic.

Veklury recently turned its emergency nod to an official approval for all hospitalized COVID-19 patients, but the broadly inclusive label has drawn controversy as the antiviral has shown very little benefit for moderately ill patients.

Anti-malaria drug chloroquine, a drug touted by President Donald Trump during the early days of the pandemic, had its emergency authorization revoked after clinical data proved it lacked antiviral effects. The FDA’s emergency nod for convalescent plasma also sparked debate.

While therapeutics represent important weapons in the fight against COVID, their commercial value may be dwindling now that Pfizer and partner BioNTech have unveiled positive early COVID vaccine news, saying their BNT162b2 was more than 90% effective in preventing the disease at an interim analysis.

An effective vaccine would mean fewer COVID-19 patients, squeezing the market for treatments. Therefore, it “should raise further questions around the mid-to-long-term durability of those revenue streams,” analysts at Barclays wrote in a Monday note to clients.

Lilly’s antibodies might be able to carve out a piece of the preventative market, though. The company is testing bamlanivimab’s ability to protect people against coronavirus infection in the phase 3 Blaze-2 study in residents and staff at long-term care facilities.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...